Everolimus posts 'big win'
Added: Thursday 3 November 2011
Results presented at ECCO suggest a marked improvement in progression-free breast cancer survival when everolimus was added to letrozole, compared to letrozole alone. The BOLERO-2 trial was carried out on women with endocrine-resistant metastatic breast cancer.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: